Abstract: Meltable compositions configured for oral use, the compositions including at least one cannabinoid or cannabimimetic, are provided. The compositions include one or more fillers, typically a sugar alcohol, and a lipid. A method of forming such compositions is also provided.

Abstract: The invention refers to a fungicide mixture comprising the biocides thiabendazole (TBZ), pyrimethanil (PYM) and fludioxonil (FDL), wherein the total amount of FDL based on the entire amount of biocidal actives is greater than 2 wt. %.

Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.

Abstract: Embodiments are directed towards methods of inducing caspase activity. The methods include contacting a cell with a treatment compound represented by the following Formula (I): where R1 is selected from hydrogen or an alkyl group having from 1 to about 16 carbon atoms; R2 is selected from a hydroxyl group, a tosylate group, an alkoxy group of the formula OR3 where R3 is selected from an alkyl group having from 1 to about 16 carbon atoms, or an ester group of the formula OCOR4, where R4 is an alkyl group having from 1 to about 16 carbon atoms, and n is from 4 to 46,000, with the proviso that when R1 is hydrogen and R2 is a hydroxy group the treatment compound has a number average molecular weight from 10,100 to 2,000,0000 g/mol.

Abstract: Formulations comprised of pyrone and a mixture of at least one cationic surfactant, such as for preservation of personal care compositions, are disclosed. Articles comprising the formulations are further disclosed.

Abstract: In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 1 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid.

Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution substantially free of organic solvent, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: Described herein are personal care compositions comprising a solid vinylpyrrolidone/vinyl acetate copolymer; a vinylpyrrolidone/vinyl acetate copolymer; and a cosmetically acceptable carrier. Methods of making and using the same are also described.

Abstract: A therapy device having transdermal and/or topical delivery features to treat myofascial and/or musculoskeletal tissue imbalances and/or treat inflammation. The therapy device is comprised of a soft tissue mobilizing device having a front surface, and a back surface having transdermal delivery features. The back surface includes a therapeutic substance disposed thereon and an adhesive to adhere the device directly to the soft tissue area of a user's body where muscle tension, aches and pain are present. The device when applied decompresses the soft tissue area being treated. The front surface includes a gripping mechanism to allow the user to grip the mechanism to manually lift and shift the soft tissue area being treated. The transdermal delivery features of the device and the manual lifting and shifting of the user's soft tissue reduces the time period for normalizing the myofascial and/or musculoskeletal tissue area being treated.

Abstract: Embodiments described herein relate to compounds for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. Further embodiments relate to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic conversion of specific substrates which are contained in the compositions. Additional embodiments relate to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Abstract: The present invention relates to a pharmaceutical preparation comprising omeprazole, an enantiomer thereof or a pharmaceutically acceptable salt thereof, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention relates to a pharmaceutical preparation in which sodium bicarbonate is first disintegrated so as to raise pH, and then omeprazole is dissolved such that the release properties of an active ingredient are improved, and thus the dissolution pattern and bioavailability of a drug can be enhanced.

Abstract: Disclosed are encapsulated perfume compositions showing improved balance between storage stability in consumer products and perfume diffusivity from intact microcapsules deposited on substrates (so-called pre-rub performance), the compositions comprising a combination of long chain aldehydes having 10 carbon atoms or more and/or tertiary alcohols having 10 carbon atoms or more, in combination with blooming perfume ingredients.

Abstract: Novel dinuclear silver(I) pyrazolido complexes and methods of synthesizing them are provided. Advantageously, the novel silver(I) pyrazolido complexes have excellent antimicrobial activity and methods of using said complexes to treat bacterial, fungal, and viral infections are also provided.

Abstract: A non-surfactant type oil-water (O/W) dispersion composition containing non-polar solvent droplets in a polar solvent, of which transparency is 90-100%, and a non-surfactant type water-oil (W/O) dispersion composition containing polar solvent droplets in a non-polar solvent, of which transparency is 90-100% are disclosed. Also disclosed are methods for manufacturing methods for both of the compositions.

Abstract: The present disclosure relates to leave-on serum hair compositions that comprise a blend of non-cyclic silicone and non-silicone ingredients. The leave-on serum hair compositions, which do not contain D4, D5 or D6 silicones, are particularly useful in methods for imparting durable resistance to breaking, frizz control, shine and/or volume definition with a soft feel to hair.

Abstract: Provided is a composition, in the form of an emulsion comprising a polyester from the esterification, with a polycarboxylic acid, of an aliphatic hydroxycarboxylic acid ester comprising at least two hydroxyl groups and at least one nonionic cellulose derivative comprising one or more hydrophobic substituents containing from 8 to 30 carbon atoms. Also provided is a composition comprising an active agent chosen from C-glucoside derivatives, a pasty fatty substance and a nonionic cellulose derivative comprising one or more hydrophobic substituents containing from 8 to 30 carbon atoms. Emulsions are made possible containing pasty fatty substances that are stable, even without an emulsifying surfactant or with a low content thereof (for example less than 3%), and which afford good sensory pleasure, even when the composition comprises a high content of pasty fatty substances. The emulsions can also contain active agents chosen from C-glucoside derivatives and cucurbic acid derivatives that are stable.

Abstract: Nanoparticles and formulations for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are disclosed. The nanoparticles contain a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying agent is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agent can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof, that inactivate ribosomes of gonadotroph cells and/or prevent or reduce secretion of follicle-stimulating hormones in the subject. Uses for formulations incorporating the nanoparticles for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are also disclosed.

Abstract: An 9-(6-fluoro-2-hydroxypyridin-3-yl)-10-(2-hydroxyethyl)-3.6-diphenyl-3,4,6,7,9,10-hexahydroacridine 1,8 (2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A shaving aid including a lubricant and a benefit agent. The benefit agent is azoxystrobin. Also provided is hair removal device with a shaving aid and the shaving aid includes azoxystrobin. The shaving aid may be on-board the hair removal device or provided separately. The shaving aid may be a solid or a liquid.